article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.

article thumbnail

How the New EU AI Act Will Impact Clinical Trials in the Life Sciences?

Cloudbyz

This Act is poised to significantly change the clinical trials landscape within the life sciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

In the life sciences sector, one country is significantly outstripping others for FDI. Data shows that almost 40% of all life sciences subsidiaries are located in the US. After all, around a third of the world’s leading life sciences corporations have their headquarters in the country. Industry clusters.

article thumbnail

6 Life Science Technology Trends for 2023

XTalks

The life science industry is constantly evolving, making it difficult to stay ahead of the curve. Digital transformation is burgeoning and we aim to cover some of the dominant emerging technologies that are currently running the life science industry by storm.

article thumbnail

eBook: Top Trending Life Science Topics for 2022

XTalks

The life science industry is dynamic and progressive with 2022 exemplifying significant growth. Agile life science companies that were able to adapt to the challenges of the pandemic and ongoing global regulations prospered since the last two years.

article thumbnail

UK regulator cuts late-stage clinical trial approval time to two weeks

Drug Discovery World

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to reduce the time taken to approve the lowest-risk clinical trials by more than 50%. According to the plans, initial applications for the lowest-risk Phase III and IV trials will be processed by the MHRA within 14 days instead of the statutory 30 days.

article thumbnail

AI and machine learning: A new era for clinical trials

Drug Discovery World

Fiona Maini , Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials.